110816-78-9Relevant academic research and scientific papers
Therapeutic agent for allergic dermatitis
-
, (2008/06/13)
A therapeutic agent for allergic dermatitis caused by type IV allergic reaction, which contains diethyl L-lysylcromoglycate of the formula: or a nontoxic salt thereof as an active ingredient. This therapeutic agent for allergic dermatitis is effective for the treatment of allergic dermatitis caused by type IV allergic reaction, such as contact dermatitis mainly induced by type IV allergic reaction and atopic dermatitis induced by type I and type IV allergic reactions.
Antirheumatic agent
-
, (2008/06/13)
PCT No. PCT/JP97/01974 Sec. 371 Date Dec. 10, 1998 Sec. 102(e) Date Dec. 10, 1998 PCT Filed Jun. 6, 1997 PCT Pub. No. WO97/47297 PCT Pub. Date Dec. 18, 1997An antirheumatic agent comprising diethyl L-lysylcromoglycate of the following formula or a nontoxic salt thereof as an active ingredient. This compound has an anti-inflammatory action and immunomodulating action, is absorbed by oral administration to be delivered efficiently to local sites, and is associated with fewer side effects, so that it serves well as an antirheumatic agent that can be administered orally.
Cromoglycic acid derivatives, method of production thereof and pharmaceutical composition
-
, (2008/06/13)
Cromoglycic acid derivatives of the general formula STR1 wherein R1 is an α-, β- or γ-amino acid residue (for ester bonding) whose amino group may optionally be substituted by at least one lower alkyl group, and R2 and R3 each independently is a lower alkyloxy-substituted or an unsubstituted lower alkyl group, an 1-alkanoyloxyalkyl group, an 1-alkoxycarbonyloxyalkyl group, a phthalidyl group or a 5-methyl-1,3-dioxol-2-on-4-ylmethyl group; nontoxic salts thereof; and pharmaceutical compositions containing such compounds. Since the compounds have antiallergic activity and are readily absorbable into the blood stream, they are useful as oral antiallergic agents.
